(DLHC) DLH Holdings - Ratings and Ratios

DLH Holdings Corp. (NASDAQ:DLHC) is a leading provider of technology-enabled business process outsourcing, program management, and public health research and analytics services in the United States. The company specializes in delivering digital transformation and cybersecurity solutions, leveraging advanced technologies such as artificial intelligence, machine learning, cloud enablement, and big data analytics. Its client base includes prominent federal agencies like the National Institutes of Health (NIH), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, and the U.S. Navy Naval Information Warfare Center (NIWC). Additionally, DLH offers science research and development services, including data analytics, testing and evaluation, clinical trials research, and epidemiology studies, supporting organizations such as the NIH, the Centers for Disease Control and Prevention (CDC), and the Military Health System. The company also provides system engineering and integration solutions for pharmaceutical delivery logistics, fire protection engineering, biomedical equipment, and technology engineering, serving the Department of Veterans Affairs, NIWC, the Department of Health and Human Services, and other federal customers. DLH’s business process management services are delivered under trademarks such as e-PRAT and SPOT-m, as well as the registered trademark Infinibyte for cloud-based solutions. Formerly known as TeamStaff, Inc., the company rebranded as DLH Holdings Corp. in June 2012. Headquartered in Atlanta, Georgia, DLH was incorporated in 1969 and operates as a trusted partner to federal and public health sectors.

Based on the provided and , DLH Holdings Corp. is expected to navigate a challenging environment over the next three months. The stock’s price has been declining, with the 20-day SMA at 5.65 and 50-day SMA at 6.90, both above the current price of 4.77, indicating bearish momentum. The 200-day SMA of 9.12 further highlights the downward trend. The ATR of 0.28 suggests moderate volatility. From a fundamental perspective, the P/E ratio of 12.16 and forward P/E of 17.45 indicate undervaluation relative to future earnings expectations. The P/B ratio of 0.69 and P/S ratio of 0.20 also signal potential undervaluation. However, the RoE of 5.71% reflects modest profitability. Over the next three months, DLHC is likely to face headwinds from technical resistance levels near 5.65 and 6.90, with potential support at its current price range. Investors should monitor earnings releases and federal contract announcements for catalysts. The stock’s low average volume of 57,603 shares suggests limited liquidity, which could amplify price movements in response to news or trading activity.